Targeting protein-protein interactions in the proteasome super-assemblies

Maria E Gaczynska, Pawel Osmulski

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Protein-protein interactions (PPI) are at the center of molecular mechanisms of life. The protein ligands convene for regulation of biological function: adding, enhancing or inhibiting activity, for assistance in structural integrity or to enable subsequent PPI. All these general roles of PPI are represented in the proteasome, the giant proteolytic factory universally present in human cells. The proteasome is a renowned target for anti-cancer drugs and a considered target for drugs curbing inflammation. The essential function of the proteasome, the degradation of a majority of intracellular proteins via the ubiquitin-proteasome pathway, relies on proper interactions between multiple subunits of the enzyme and between multiple modules forming distinct super-assemblies covered by the “proteasome” name. The interface regions between constitutive, alternative or transient protein components of the proteasome provide a rich platform for design of drugs with potentially very diverse actions. Still, the resource remains largely untapped since all proteasometargeting drugs used so far in humans are classical competitive inhibitors blocking catalytic centers. In this review, we will discuss the opportunities and challenges of targeting PPI in the hub enzyme for intracellular protein catabolism, the proteasome.

Original languageEnglish (US)
Pages (from-to)2056-2067
Number of pages12
JournalCurrent Topics in Medicinal Chemistry
Volume15
Issue number20
StatePublished - Jul 1 2015

Fingerprint

Protein Transport
Proteasome Endopeptidase Complex
Proteins
Pharmaceutical Preparations
Drug Design
Enzymes
Ubiquitin
Names
Ligands
Inflammation

Keywords

  • Allostery
  • Cancer
  • Drugs
  • Inhibitors
  • Proteasome
  • Protein-protein interactions
  • Proteolysis
  • Ubiquitin-proteasome pathway

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Targeting protein-protein interactions in the proteasome super-assemblies. / Gaczynska, Maria E; Osmulski, Pawel.

In: Current Topics in Medicinal Chemistry, Vol. 15, No. 20, 01.07.2015, p. 2056-2067.

Research output: Contribution to journalArticle

@article{b8f29597d5ad413791625428d97e92cf,
title = "Targeting protein-protein interactions in the proteasome super-assemblies",
abstract = "Protein-protein interactions (PPI) are at the center of molecular mechanisms of life. The protein ligands convene for regulation of biological function: adding, enhancing or inhibiting activity, for assistance in structural integrity or to enable subsequent PPI. All these general roles of PPI are represented in the proteasome, the giant proteolytic factory universally present in human cells. The proteasome is a renowned target for anti-cancer drugs and a considered target for drugs curbing inflammation. The essential function of the proteasome, the degradation of a majority of intracellular proteins via the ubiquitin-proteasome pathway, relies on proper interactions between multiple subunits of the enzyme and between multiple modules forming distinct super-assemblies covered by the “proteasome” name. The interface regions between constitutive, alternative or transient protein components of the proteasome provide a rich platform for design of drugs with potentially very diverse actions. Still, the resource remains largely untapped since all proteasometargeting drugs used so far in humans are classical competitive inhibitors blocking catalytic centers. In this review, we will discuss the opportunities and challenges of targeting PPI in the hub enzyme for intracellular protein catabolism, the proteasome.",
keywords = "Allostery, Cancer, Drugs, Inhibitors, Proteasome, Protein-protein interactions, Proteolysis, Ubiquitin-proteasome pathway",
author = "Gaczynska, {Maria E} and Pawel Osmulski",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
volume = "15",
pages = "2056--2067",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "20",

}

TY - JOUR

T1 - Targeting protein-protein interactions in the proteasome super-assemblies

AU - Gaczynska, Maria E

AU - Osmulski, Pawel

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Protein-protein interactions (PPI) are at the center of molecular mechanisms of life. The protein ligands convene for regulation of biological function: adding, enhancing or inhibiting activity, for assistance in structural integrity or to enable subsequent PPI. All these general roles of PPI are represented in the proteasome, the giant proteolytic factory universally present in human cells. The proteasome is a renowned target for anti-cancer drugs and a considered target for drugs curbing inflammation. The essential function of the proteasome, the degradation of a majority of intracellular proteins via the ubiquitin-proteasome pathway, relies on proper interactions between multiple subunits of the enzyme and between multiple modules forming distinct super-assemblies covered by the “proteasome” name. The interface regions between constitutive, alternative or transient protein components of the proteasome provide a rich platform for design of drugs with potentially very diverse actions. Still, the resource remains largely untapped since all proteasometargeting drugs used so far in humans are classical competitive inhibitors blocking catalytic centers. In this review, we will discuss the opportunities and challenges of targeting PPI in the hub enzyme for intracellular protein catabolism, the proteasome.

AB - Protein-protein interactions (PPI) are at the center of molecular mechanisms of life. The protein ligands convene for regulation of biological function: adding, enhancing or inhibiting activity, for assistance in structural integrity or to enable subsequent PPI. All these general roles of PPI are represented in the proteasome, the giant proteolytic factory universally present in human cells. The proteasome is a renowned target for anti-cancer drugs and a considered target for drugs curbing inflammation. The essential function of the proteasome, the degradation of a majority of intracellular proteins via the ubiquitin-proteasome pathway, relies on proper interactions between multiple subunits of the enzyme and between multiple modules forming distinct super-assemblies covered by the “proteasome” name. The interface regions between constitutive, alternative or transient protein components of the proteasome provide a rich platform for design of drugs with potentially very diverse actions. Still, the resource remains largely untapped since all proteasometargeting drugs used so far in humans are classical competitive inhibitors blocking catalytic centers. In this review, we will discuss the opportunities and challenges of targeting PPI in the hub enzyme for intracellular protein catabolism, the proteasome.

KW - Allostery

KW - Cancer

KW - Drugs

KW - Inhibitors

KW - Proteasome

KW - Protein-protein interactions

KW - Proteolysis

KW - Ubiquitin-proteasome pathway

UR - http://www.scopus.com/inward/record.url?scp=84937129018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937129018&partnerID=8YFLogxK

M3 - Article

C2 - 25986687

AN - SCOPUS:84937129018

VL - 15

SP - 2056

EP - 2067

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 20

ER -